Business- Page 47

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today

Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels more than doubled in nearly all patients after one cycle of treatment Substantial increases in HPV-16-specific

MGX-001 data establish preclinical proof-of-concept in hemophilia AOn track to initiate global clinical trial in 2027 EMERYVILLE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an

Upcoming Winter Launches of New Models in Sizes of 20’’ 44” 52” and 60” are Expected in Home Depot, Lowes, Target, Walmart, Amazon and on Company’s E-Commerce Platform  Management Anticipates New Turbo

–  Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT – LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us”

LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced

Eligible U.S. Feedonomics customers can now use the Merchant Workspace to connect their catalogs to Shop Direct and reach shoppers searching for their products AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) —

SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world

Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors. Ronde-cel, a next-generation CD19/CD20 CAR T-cell product